Population Pharmacokinetic Modelling of Plasma & Intracellular Once Daily Ritonavir-
Boosted Darunavir in HIV-Infected Patie Page 1 Presented at the 12th Int. Workshop on Clin …

Poor metabolisers of CYP2B6 (PM) require a lower dose of efavirenz because of serious
adverse reactions resulting from the higher plasma concentrations associated with a …

We developed a novel HIV-1 dynamic model with consideration of pharmacokinetics, drug
adherence and drug susceptibility to link plasma drug concentration to the long-term …

Interindividual variability in drug response depends on a number of genetic and
environmental factors. The metabolic enzymes are well known for their contribution to this …

Quantification of interindividual variability and determination of the covariates contributing to
this variability have proved to improve decision-making procedures and individualization of …

Population pharmacokinetics is the study of sources and correlates of variability in drug
exposure and response. The study of population pharmacokinetics represents an important …

Objective: To estimate individual and population postinduction pharmacokinetics of
carbamazepine (CBZ) in epileptic adult and paediatric patients who received chronic CBZ …

Physiologically based pharmacokinetic (PBPK) models have gained in popularity in the last
decade in both drug development and regulatory science. PBPK models differ from classical …

Objective This work aimed at building a population pharmacokinetic (PK) model for
lamivudine (LMV), stavudine (STV) and zidovudine (ZDV), estimating their inter and …

The coformulated lopinavir/ritonavir significantly reduces quinine concentration in healthy
volunteers due to potential drug–drug interactions (DDIs). However, DDI information in …